Clifford Swan Investment Counsel LLC Has $16.93 Million Stock Position in Bristol Myers Squibb Company $BMY

Clifford Swan Investment Counsel LLC reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 2.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 293,833 shares of the biopharmaceutical company’s stock after selling 7,632 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Bristol Myers Squibb were worth $16,931,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Swiss RE Ltd. acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb during the second quarter worth $27,000. Bayban bought a new position in Bristol Myers Squibb during the fourth quarter worth $31,000. Finally, Addison Advisors LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $66.93 on Tuesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company’s 50 day moving average price is $62.01 and its two-hundred day moving average price is $59.72. The stock has a market cap of $136.72 billion, a P/E ratio of 14.74, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Cantor Fitzgerald restated a “neutral” rating and issued a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Citigroup reiterated a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Finally, Bank of America reduced their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.